The realization of direct-acting agents targeting the MYC oncogene has been a long-standing challenge in cancer therapeutics. Our recent paper describes new antisense tools with potent anti-MYC effects.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us